# A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases

> **NCT04523207** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 108 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Apalutamide
- **DRUG:** ADT
- **DRUG:** Relugolix

## Key facts

- **NCT ID:** NCT04523207
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-19
- **Primary completion:** 2023-10-23
- **Final completion:** 2023-10-25
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04523207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04523207, "A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04523207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*